Evidence map›Paper›PMID 27432602›Full record

ArticleThe Journal of antimicrobial chemotherapy2016

The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization.

Magnus Unemo, Daniel Golparian, Leonor Sánchez-Busó, Yonatan Grad, Susanne Jacobsson, Makoto Ohnishi, Monica M Lahra, Athena Limnios, Aleksandra E Sikora, Teodora Wi and 1 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Genomic analysis ofMicrobiology spectrum · 2026
    Article
  3. Antimicrobial agents and chemotherapy · 2026
    Article
  4. An antibody-drug conjugate active against antibiotic-resistantProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Restriction-modification systems are required forProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Establishing aMicrobiology spectrum · 2026
    Article
  12. Biology of novel LpxC inhibitors forMicrobiology spectrum · 2026
    Article
  13. Restriction-modification systems are required forbioRxiv : the preprint server for biology · 2026
    Article
  14. Article
  15. Repurposing epetraborole to combatAntimicrobial agents and chemotherapy · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. [A NovelSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  20. Microbiology spectrum · 2025
    Article

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Magnus UnemoWHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden magnus.unemo@regionorebrolan.se.
Daniel GolparianWHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Leonor Sánchez-BusóPathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridgeshire, UK.
Yonatan GradDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Susanne JacobssonWHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Makoto OhnishiDepartment of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Monica M LahraWHO Collaborating Centre for Sexually Transmitted Diseases, Department of Microbiology, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, Sydney, Australia.
Athena LimniosWHO Collaborating Centre for Sexually Transmitted Diseases, Department of Microbiology, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, Sydney, Australia.
Aleksandra E SikoraDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.
Teodora WiDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Simon R HarrisPathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridgeshire, UK.

Funding

Proteomics-Driven Reverse Vaccinology for GonorrheaR01AI117235 · NIAID · OREGON STATE UNIVERSITY · PI Aleksandra Elzbieta Sikora · 2015 to 2026
$6.7M
Genomic epidemiology of Neisseria gonorrhoeae with elevated MICs to cefiximeK08AI104767 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI GRAD, YONATAN H · 2013 to 2015
$547k
NIAID NIH HHS K08 AI104767NIAID NIH HHS R01 AI117235Wellcome Trust 098051
6 · The paper itself

Abstract

objectivesGonorrhoea and MDR Neisseria gonorrhoeae remain public health concerns globally. Enhanced, quality-assured, gonococcal antimicrobial resistance (AMR) surveillance is essential worldwide. The WHO global Gonococcal Antimicrobial Surveillance Programme (GASP) was relaunched in 2009. We describe the phenotypic, genetic and reference genome characteristics of the 2016 WHO gonococcal reference strains intended for quality assurance in the WHO global GASP, other GASPs, diagnostics and research worldwide.

methodsThe 2016 WHO reference strains (n = 14) constitute the eight 2008 WHO reference strains and six novel strains. The novel strains represent low-level to high-level cephalosporin resistance, high-level azithromycin resistance and a porA mutant. All strains were comprehensively characterized for antibiogram (n = 23), serovar, prolyliminopeptidase, plasmid types, molecular AMR determinants, N. gonorrhoeae multiantigen sequence typing STs and MLST STs. Complete reference genomes were produced using single-molecule PacBio sequencing.

resultsThe reference strains represented all available phenotypes, susceptible and resistant, to antimicrobials previously and currently used or considered for future use in gonorrhoea treatment. All corresponding resistance genotypes and molecular epidemiological types were described. Fully characterized, annotated and finished references genomes (n = 14) were presented.

conclusionsThe 2016 WHO gonococcal reference strains are intended for internal and external quality assurance and quality control in laboratory investigations, particularly in the WHO global GASP and other GASPs, but also in phenotypic (e.g. culture, species determination) and molecular diagnostics, molecular AMR detection, molecular epidemiology and as fully characterized, annotated and finished reference genomes in WGS analysis, transcriptomics, proteomics and other molecular technologies and data analysis.

Indexed as

Reference StandardsAnti-Bacterial AgentsGenes, BacterialGenome, BacterialGenotypeGonorrheaHumansMicrobial Sensitivity TestsMolecular TypingNeisseria gonorrhoeaePlasmidsQuality Assurance, Health CareSerogroupAnti-Bacterial Agents

Identifiers

PMID27432602
PMCPMC5079299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.